Applying dioscin to A549 and H1299 lung cancer cells causes a dose-dependent increase in Erk1/2 and JNK1/2 activities, while reducing PI3K expression and Akt and mTOR phosphorylation (Hsieh et al., 2013). Here, MAPK3 is linked to lung cancer.